Watt's disease (hyperparathyroidism) - Symptoms, Causes, Treatment & Prevention

Overview

Watt’s disease is the historic name for **primary hyperparathyroidism (PHPT)**, a condition in which one or more of the parathyroid glands produce excess parathyroid hormone (PTH). PTH regulates calcium and phosphate metabolism; when it is too high, calcium is released from bone, re‑absorbed in the kidneys, and absorbed from the gut, leading to hypercalcemia.

Although it can affect any age group, PHPT most commonly appears in post‑menopausal women. In the United States, about 1–2% of the adult population has biochemically confirmed PHPT, and up to 7% of women over 55 years old have the disease[^1][^2]. The condition is named after Dr. *James Watt*, a Scottish surgeon who first described it in the early 20th century.

Symptoms

Many patients are diagnosed incidentally through routine blood work that shows high calcium. When symptoms do arise, they are often described by the mnemonic “**Stones, Bones, Groans, Moans, and Psychiatric overtones**.” Below is a comprehensive list.

Renal (Kidney) Manifestations

• Nephrolithiasis (Kidney stones): Calcium‑oxalate stones cause flank pain, hematuria, and urinary urgency.
• Nephrocalcinosis: Diffuse calcium deposition in renal parenchyma can lead to chronic kidney disease.
• Polyuria & Polydipsia: High calcium interferes with concentrating ability of the kidneys.

Skeletal Manifestations

• Bone pain: Typically dull, aching pain in the lower back, hips, or ribs.
• Fractures: Pathologic fractures of the wrist, hip, or vertebrae due to reduced bone density (osteoporosis).
• Subperiosteal bone resorption: Seen on X‑ray of the phalanges; considered pathognomonic.
• Brown tumors: Lytic bone lesions that can mimic metastatic disease.

Gastro‑intestinal Manifestations

• Abdominal pain or cramping.
• Nausea & vomiting.
• Constipation due to reduced gut motility.
• Peptic ulcer disease and pancreatitis (rare but reported).

Neuro‑psychiatric Manifestations

• Fatigue, weakness, and muscle aches.
• Depression, irritability, or anxiety.
• Cognitive changes: Difficulty concentrating, “brain fog.”
• Psychosis or delirium in severe hypercalcemia.

Cardiovascular Manifestations

• Hypertension (observed in up to 30% of patients).
• Shortened QT interval on ECG; rarely, cardiac arrhythmias.
• Calcific deposition in coronary arteries (long‑term risk).

Other Signs

• Dry mouth, excessive thirst.
• Joint stiffness.
• Weight loss (if severe GI symptoms).

Causes and Risk Factors

Primary hyperparathyroidism is caused by **autonomous over‑production of PTH** from one or more parathyroid glands. The underlying pathology falls into three main categories:

1. Single adenoma (≈80% of cases) – a benign tumor of one gland.
2. Hyperplasia of two or more glands (≈15%).
3. Parathyroid carcinoma (≈1–2%).

Genetic & Familial Syndromes

• Multiple Endocrine Neoplasia type 1 (MEN‑1)
• MEN‑2A (RET mutations)
• Familial hypocalciuric hypercalcemia (FHH) – often mistaken for PHPT but does not require surgery.

Risk Factors

• Age & gender: Women >50 years are at highest risk.
• Radiation exposure: Prior head/neck radiation increases risk of adenomas.
• Chronic lithium therapy: Used for bipolar disorder; can cause hyperparathyroidism.
• Vitamin D deficiency: May mask hypercalcemia and delay diagnosis.
• Kidney disease: Although secondary hyperparathyroidism is more common, CKD patients can develop autonomous gland hyperfunction.

Diagnosis

The diagnostic work‑up aims to (1) confirm hypercalcemia, (2) verify inappropriately elevated PTH, and (3) assess disease severity and complications.

1. Laboratory Tests

• Serum calcium (total or ionized): Elevated >10.5 mg/dL (2.62 mmol/L) in most adults.
• Parathyroid hormone (intact PTH): Inappropriately normal or high (>65 pg/mL) despite hypercalcemia.
• Serum phosphate: Usually low or low‑normal because PTH promotes renal phosphate excretion.
• 25‑hydroxy vitamin D: Measured to guide supplementation; deficiency is common.
• 24‑hour urinary calcium: Helps differentiate PHPT from FHH ( urinary calcium <100 mg/day in FHH).
• Creatinine & eGFR: Baseline kidney function.

2. Imaging Studies

• Neck Ultrasound: First‑line for locating enlarged glands; sensitivity ≈70%.
• Sestamibi (Tc‑99m) Scintigraphy: Functional imaging; combined with ultrasound can localize >90% of single adenomas.
• 4‑D CT scan: High‑resolution anatomic + perfusion data; useful for re‑operative cases.
• Dual‑energy X‑ray Absorptiometry (DEXA): Assesses bone mineral density; osteoporosis is present in 30‑50% of untreated patients.
• Kidney imaging (ultrasound/CT): Evaluates for stones or nephrocalcinosis.

Diagnostic Criteria (per 2022 Endocrine Society Guidelines)

PHPT is diagnosed when **serum calcium is elevated** and **PTH is not suppressed** (i.e., within or above the reference range). Additional criteria such as low‑normal urinary calcium, presence of end‑organ damage (bone loss, stones, gastrointestinal symptoms), or markedly high PTH (>3× upper limit) can help decide on surgery.

Treatment Options

Management is individualized based on age, symptom burden, calcium level, bone density, and surgical risk.

1. Surgical Intervention – the definitive cure

• Minimally invasive parathyroidectomy (MIP): Preferred for a single adenoma; uses pre‑operative localization, a small incision, and intra‑operative PTH monitoring.
• Bilateral neck exploration: Reserved for multigland disease or when localization fails.
• Success rates: 95–98% cure with low complication rates (hypocalcemia, recurrent laryngeal nerve injury <1%).

2. Medical Management (when surgery is contraindicated or deferred)

1. Hydration & calcium restriction: 2–3 L of isotonic saline daily; limit dietary calcium to 800–1000 mg.
2. Bisphosphonates (e.g., alendronate): Reduce bone resorption and modestly lower serum calcium.
3. Calcimimetics (cinacalcet): Increase the sensitivity of the calcium‑sensing receptor, lowering PTH and calcium; indicated for patients who cannot undergo surgery.
4. Vitamin D supplementation: Correct deficiency (cholecalciferol 800–2000 IU daily) but monitor calcium closely.
5. Loop diuretics (e.g., furosemide): Only after adequate hydration to promote calciuresis.

3. Lifestyle Adjustments

• Stay well‑hydrated (≥2 L water/day).
• Engage in weight‑bearing exercise (30 min most days) to protect bone.
• Avoid excessive sodium and animal protein, which increase calcium excretion.
• Limit alcohol and quit smoking – both worsen bone loss.

Living with Watt’s Disease (hyperparathyroidism)

Even after successful treatment, regular follow‑up is essential.

Monitoring Schedule

• Post‑operative: Calcium and PTH at 24 h, 1 week, and 6 months.
• Long‑term: Calcium, PTH, renal function, and DEXA every 1–2 years.

Practical Tips

1. Know your labs: Keep a copy of recent calcium/PTH results and share with any new physician.
2. Medication review: Some drugs (thiazide diuretics, lithium) can raise calcium; discuss alternatives with your provider.
3. Bone health: Ensure adequate calcium (1200 mg) and vitamin D (800–1000 IU) intake unless contraindicated.
4. Kidney vigilance: If you develop flank pain, visible blood in urine, or a change in urinary frequency, seek evaluation for possible stones.
5. Symptom diary: Record episodes of fatigue, mood changes, or GI upset to discuss at appointments.

Prevention

Because most PHPT cases are sporadic and not preventable, primary prevention focuses on modifiable risk factors and early detection.

• Maintain adequate vitamin D and calcium levels through diet or supplements.
• Avoid long‑term use of medications that affect calcium metabolism unless medically necessary.
• Periodic laboratory screening (serum calcium) for high‑risk groups – especially women >50 y, patients with a family history of endocrine tumors, or those on lithium.
• Limit radiation exposure to the head/neck region when possible.

Complications

If left untreated, chronic hyperparathyroidism can lead to serious, sometimes irreversible, complications:

• Osteoporosis & fractures: Up to 50% develop decreased bone mineral density.
• Nephrolithiasis & chronic kidney disease: Recurrent stones may cause obstructive nephropathy.
• Cardiovascular disease: Hypertension, left‑ventricular hypertrophy, and increased mortality have been linked to prolonged hypercalcemia.
• Neuro‑psychiatric morbidity: Persistent depression, cognitive decline, and reduced quality of life.
• Pancreatitis: Though rare, severe hypercalcemia can precipitate acute pancreatitis.
• Parathyroid carcinoma: Although rare, delayed diagnosis may allow malignant progression.

When to Seek Emergency Care

References

• [^1]: National Institute of Diabetes and Digestive and Kidney Diseases. “Hyperparathyroidism.” NIH, 2023. https://www.niddk.nih.gov/health-information/endocrine-diseases/hyperparathyroidism
• [^2]: Silverberg SJ, Bilezikian JP. “Primary hyperparathyroidism.” New England Journal of Medicine. 2020;382: 2365‑2375. DOI:10.1056/NEJMra1917646
• Mayo Clinic. “Primary hyperparathyroidism.” 2022. https://www.mayoclinic.org
• Cleveland Clinic. “Hyperparathyroidism.” 2023. https://my.clevelandclinic.org
• Endocrine Society Clinical Practice Guideline. “Management of Primary Hyperparathyroidism.” 2022.
• World Health Organization. “Guidelines on Calcium and Vitamin D Supplementation.” 2021.